Novel Rx
Nouf Al hemmadi NoufAhmedAlham2
3 months ago
Progressive BiTE in SLE 2 https://t.co/ykMQmSAdlb
More on BiTES in SLE by the one and only @Yuz6Yusof
Bi specific Tcell engager ( CD3-CD19).
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2
3 months ago
New Paradigms in RA Treatment https://t.co/CqpI2znglE
@jeffsparks Highlights new trials in RA
1-Neuro immune modulation ( Vagal nerve stimulation).
2-Targeting pathogenic T cells
3-T reg CAR-T ( Peace maker).
@RheumNow
#ACR25
CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.
A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease.
Brian Jaros, MD Dr_Brian_MD
3 months ago
IL-5 agents may in fact work for severe EGPA manifestations
Although severe pt were excluded from enrollment in MANDARA, post-hoc and OLE data suggest development of severe manifestations is rare in benra treated patients
@RheumNow #ACR25 https://t.co/slUpAT9mWo
Akhil Sood MD, MS AkhilSoodMD
3 months ago
Abstract 1657: Can LLMs track medication history? GPT-4 outperformed most LLMs in identifying TNFi start/stop events and reasons for switch. 💊 Common reasons for TNFi switching: lack of effectiveness, adverse events, and insurance/cost barriers. @RheumNow #ACR25 https://t.co/5FUR9tBoyu
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB
Mike Putman EBRheum
3 months ago
New tx for IPF/autoimmune ILD, nerandomilast (PDE4Bi)
Subgroup analysis from FIBRONEER-ILD, marginally less FVC worsening (-65mL tx grp vs -107mL plbo grp) & no clear improvements in dyspnea/fatigue/cough
But also... 6% absolute reduction in overall, persisted (small n) in https://t.co/Faf26UZuDx
Jiha Lee JihaRheum
3 months ago
Beyond biologics: RA meets bioelectric medicine.
In RESET-RA, TNFi inadequate response or intolerant (n=124), vagus nerve stimulation led to significant & durable improvement
🔹 ACR20 3mo: 42% active vs 18% sham (p=0.0057)
🔹 Benefits through 12mo
@RheumNow #ACR25 A#1675
sheila RHEUMarampa
3 months ago
This study evaluated effectiveness of SEC in PsA prevention of a subgroup of pts from SELENA: PsO pts w/o PsA & nail dse (n=292)
At 5 yrs:
🎯98.3% didn't develop PsA (yEAIR 0.49)
🎯 Sustained PASI, PGA 0/1
💡Longterm SEC effective for PsA prevention?
#ACR25 @RheumNow Abs1463 https://t.co/t7P1Oerbrw
Poster Hall